Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 543Squamous Cell Carcinoma of Head and Neck 280Head and Neck Neoplasms 257Lung Neoplasms 240Uterine Cervical Neoplasms 180Stomach Neoplasms 172Esophageal Neoplasms 161Nasopharyngeal Carcinoma 127Urinary Bladder Neoplasms 117Neoplasms 115Esophageal Squamous Cell Carcinoma 115Small Cell Lung Carcinoma 105Ovarian Neoplasms 92Breast Neoplasms 92Neoplasm Metastasis 89Cholangiocarcinoma 76Carcinoma, Squamous Cell 76Pancreatic Neoplasms 72Biliary Tract Neoplasms 71Oropharyngeal Neoplasms 57Mesothelioma, Malignant 57Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 46Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Gallbladder Neoplasms 39

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Observation 3Neoadjuvant Therapy 3Epirubicin 3Endoscopy 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Monatide (IMS 3015) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pathologic Complete Response × Cisplatin × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT04781725 2021-11-17

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Ottawa Hospital Research Institute

Phase 2 Unknown
90 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Krankenhaus Nordwest

Phase 2/3 Completed
716 enrolled
Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡